McMillan Office’s Ingevity NGVT Stock Holding History

McMillan Office’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.1K	Hold	216	–	–	﹤0.01%	372
2026 Q1	$15.4K	Hold	216	–	–	﹤0.01%	366
2025 Q4	$12.8K	Buy	+216	New	+$11.7K	﹤0.01%	369

Other funds holding NGVT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

McMillan Office's NGVT Position: Q2 2026 in Review

McMillan Office held its Ingevity (NGVT) position steady in Q2 2026 at 216 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #372.

McMillan Office first reported a position in NGVT in Q4 2025 and has held it in 3 quarters since. 316 funds tracked by Wall St. Rank hold NGVT as of Q2 2026.

McMillan Office held 216 shares of Ingevity worth $16.1K as of Q2 2026.
McMillan Office left its Ingevity share count unchanged in Q2 2026.
Ingevity made up ﹤0.01% of McMillan Office's portfolio in Q2 2026, its #372 holding.
McMillan Office first reported a position in Ingevity in Q4 2025 and has held it in 3 quarters since.
316 funds tracked by Wall St. Rank held Ingevity as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.